Details of the Drug

General Information of Drug (ID: DMVYXFK)

Drug Name

TAK-755

Synonyms

ADAMTS13

Indication

Disease Entry	ICD 11	Status	REF
Congenital thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[1]
Thrombotic thrombocytopenic purpura	3B64.14	Phase 3	[2]
------------------------------------------------------------------------------------

Drug Type

Enzyme replacement

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13)	TTUREBK	ATS13_HUMAN	Replacement	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05770219) Expanded Access Program: TAK-755 (rADAMTS13) for the Prophylaxis and Treatment of Severe Congenital or Hereditary Thrombotic Thrombocytopenic Purpura. U.S.National Institutes of Health.
2	ClinicalTrials.gov (NCT03393975) A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]). U.S.National Institutes of Health.
3	Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica. 2022 Nov 1;107(11):2650-2660.